Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Deal Watch: Troubled Antibiotics Maker Cempra Exploring Strategic Options

Mar 13 2017

• By Joseph Haas and Lucie Ellis-Taitt

DealWatch_1200x675

Related Content

Epidemiology First: MedImmune Moving Ahead With Preventive Antibodies, But Needs More HAP Data

Sep 25 2014

The First LPAD? Cempra May Try New Pathway For MRSA Antibiotic, Could Retrofit Solithromycin

Mar 07 2017

WHO Publishes List Of Pathogen Threats To Rouse Drug Developers

Mar 01 2017

Vertex Plays Defense In CF With Concert Deal

Mar 06 2017

Allergan Exits <em>Noctiva</em> Partnership With Serenity Just As FDA Approves Controversial Drug

Mar 07 2017

Merck's Biosims Business: What's For Sale And Who Will Buy It?

Mar 10 2017

Solithera’s Prospects Look Grim Following Complete Response Letter

Dec 30 2016

Related Companies

Melinta Therapeutics, Inc.

Seelos Therapeutics, Inc.

Ferring Pharmaceuticals

Scorpius Holdings, Inc.

Sanofi

MedImmune LLC

AstraZeneca PLC

AIMM Therapeutics B.V.

Cadent Therapeutics

Cadent Therapeutics

Saniona AB

Biogen, Inc.

Novartis AG

Les Laboratoires Servier

Ligand Pharmaceuticals, Inc.

Theratechnologies Inc.

TaiMed Biologics, Inc.

Merck KGaA

Vertex Pharmaceuticals Incorporated

Serenity Pharmaceuticals LLC

Allergan plc

Concert Pharmaceuticals, Inc.

Additional Topics

Deals M & A Business Strategies Commercial BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window